title: Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
abstract: The recent approval of adalimumab as the first treatment to be approved for the management of hidradenitis suppurativa has represented a before and after in the control of this chronic inflammatory disease. Given the inflammatory burden of this cutaneous disease, in the last few years hidradenitis suppurativa has been compared with inflammatory bowel disease, particularly with Crohn disease, to the point of considering hidradenitis suppurativa as "Crohn disease of the skin". These two chronic inflammatory diseases show sufficient similarities to consider whether treatment response based on the inflammatory load could also be similar. The present article aims to analyse the efficacy of adalimumab in hidradenitis suppurativa in comparison with a truly comparable disease, Crohn disease, with a view to evaluating therapeutic response rates and to drawing conclusions on the therapeutic success obtained in this disabling cutaneous disease.
authors.affiliation: Servicio de Dermatología, Hospital Punta de Europa, Algeciras, Cádiz, España.
authors.forename: B
authors.initials: B
authors.lastname: Moyano
authors.affiliation: Servicio de Gastroenterología, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors.forename: A
authors.initials: A
authors.lastname: Clemente
authors.affiliation: Servicio de Gastroenterología, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, España.
authors.forename: I
authors.initials: I
authors.lastname: Marín-Jiménez
authors.affiliation: Servicio de Dermatología, Hospital de Manises, Valencia, España. Electronic address: antmarto@hotmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Martorell
mesh_terms: D000038:Abscess / Q000188:drug therapy / Q000209:etiology; D000068879:Adalimumab / Q000009:adverse effects / Q000627:therapeutic use*; D001685:Biological Factors / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy; D017577:Cutaneous Fistula / Q000188:drug therapy / Q000209:etiology; D019468:Disease Management; D017497:Hidradenitis Suppurativa / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007412:Intestinal Fistula / Q000188:drug therapy / Q000209:etiology; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D001685:Biological Factors; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
keywords: Acné inverso; Adalimumab; Colitis ulcerosa; Crohn disease; Enfermedad de Crohn; Enfermedad inflamatoria intestinal; Hidradenitis suppurativa; Hidradenitis supurativa; Hidrosadenitis suppurative; Hidrosadenitis supurativa; Inflammatory bowel disease; Inverse acne; Ulcerative colitis